Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ed28726de9f916f355f8adc331e736b8 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-57 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N- http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00 |
filingDate |
2006-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2010-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67a76c18dc6da779af3bb1ebfdd5630d |
publicationDate |
2010-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-7790673-B2 |
titleOfInvention |
Methods and compositions relating to cystatin C |
abstract |
A method of treating amyloidoses by administering an effective amount of a cystatin C composition. A method of preventing and inhibiting Aβ oligomerization by administering an effective amount of a cystatin C composition. A composition for inhibiting Aβ oligomerization including an effective amount of a cystatin C composition. A method of diagnosing disease by assaying for a biomarker comprising a cystatin C complex. A biomarker for disease including a cystatin C complex. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009149394-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8470781-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020230218-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010234568-A1 |
priorityDate |
2003-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |